Key clinical point:
Major finding: With a median follow-up of 50.4 months, progression-free survival was not significantly different for escalated BEACOPP vs. the experimental arm (HR, 1.084; 95% CI, 0.73-1.59; P = .68).
Study details: Final analysis of AHL2011 LYSA, a randomized phase 3 study including 823 patients with advanced-stage Hodgkin lymphoma.
Disclosures: Dr. Casasnovas reported financial ties to AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Merck, Roche/Genentech, Sanofi, and Takeda.
Source: Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
This Week's Must Reads
Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22
Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research
Watch for RBC adhesion in men with sickle cell , Annual meeting of the Foundation for Sickle Cell Disease Research
FDA approves Jivi for hemophilia A, Package insert, news release
Marzeptacog alfa demonstrates efficacy as prophylaxis in hemophilia, Levy H et al. 2018 Hemophilia Drug Development Summit
Must Reads in Aggressive Lymphomas
Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282
First-line ibrutinib has long-term survival benefit, Barr PM et al. Haematologica. 2018;103(9):1502-10.
ctDNA may predict survival, treatment response in DLBCL, Kurtz DM et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.78.5246.
Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.
Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma, University Hospitals Cleveland Medical Center press statement